Matrix metalloproteinases and their role in pancreatic cancer: A review of preclinical studies and clinical trials

被引：71

作者：

Bloomston, M ^{[1
]}

Zervos, EE ^{[1
]}

Rosemurgy, AS ^{[1
]}

机构：

[1] Univ S Florida, Dept Surg, Tampa, FL 33601 USA

来源：

ANNALS OF SURGICAL ONCOLOGY | 2002年 / 9卷 / 07期

关键词：

pancreatic cancer; matrix metalloproteinase; MMP; TIMP;

D O I：

10.1245/aso.2002.9.7.668

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Matrix metalloproteinases (MMPs) have received much attention in recent years for their role in a variety of malignancies. Pancreatic cancer is no exception; MMP-2 and MMP-9 show high levels of expression in clinical and experimental models. Inhibition of MMPs has shown great promise with synthetic inhibitors, such as BB-94, as tumorostatic agents in preclinical models, particularly when these are combined with gemcitabine. These findings have led to several clinical trials using the MMP inhibitors Marimastat and BAY12-9566. Herein, we discuss the roles of MMPs and their inhibition in pancreatic cancer.

引用

页码：668 / 674

页数：7

共 77 条

[51]

Nemunaitis J, 1998, CLIN CANCER RES, V4, P1101

[52] FURIN-DEPENDENT INTRACELLULAR ACTIVATION OF THE HUMAN STROMELYSIN-3 ZYMOGEN [J].